Boehringer Ingelheim and Sosei Heptares entered a global collaboration and exclusive option-to-license agreement to develop and commercialize Sosei Heptares’ portfolio of first-in-class GPR52 agonists, a novel G protein-coupled receptor (GPCR) target, to improve patient outcomes by simultaneously addressing positive, negative, and cognitive symptoms of schizophrenia.   Schizophrenia is affects about 1 in 100 people worldwide. It is characterized by three clusters of symptoms: such as psychosis...